Vaxcyte (PCVX) CFO Andrew Guggenhime Buys $54K of Stock

Vaxcyte Executive Adds to Position

President and CFO Andrew Guggenhime of Vaxcyte, Inc. picked up 10,000 shares of PCVX stock on June 18, 2026. The transaction, executed at a price of $5.35 per share, totaled $53,500 according to a recent Form 4 filing with the Securities and Exchange Commission.

Where PCVX Stock Trades Today

Trading near $51.35, the biotechnology company's shares sit well above their 52-week low of $31.89 and below the 52-week high of $65.00. The stock is hovering near its 200-day moving average of $54.61 while looking toward the company's upcoming earnings release scheduled for November 3, 2026.

Recent Insider Transactions at Vaxcyte

Executive activity around the same date included several other trades by company leadership. On June 18, 2026, Chief Executive Officer Grant Pickering bought 225 shares at an average price of $1.79 for a total value of $402.75. On the same day, Andrew Guggenhime also completed a planned sale of 10,000 shares at $53.00 apiece, totaling $530,000. Additionally, CEO Grant Pickering disposed of 23,461 shares in a planned transaction at $52.50 per share, amounting to $1,231,704.85.

Wall Street Analyst Outlook for Vaxcyte

Analyst sentiment remains broadly positive as multiple firms update their outlooks. On October 12, 2026, Cantor Fitzgerald reiterated its Overweight rating with a $120.00 price target. Earlier in the month on October 5, 2026, BTIG reiterated a Buy rating and set an $89.00 price target. Needham maintained its Buy rating while raising its price target to $122.00 from $110.00 on October 5, 2026, and Guggenheim maintained a Buy rating with a target lifted to $125.00 from $116.00. B of A Securities maintained a Buy rating on September 28, 2026, with a target of $130.00, and Needham reiterated a Buy rating with a $110.00 target on September 25, 2026. Overall, the stock holds a strong buy recommendation across nine analyst opinions with a mean price target of $109.00.

Inside Vaxcyte Operations

Vaxcyte, Inc. operates as a clinical-stage vaccine company focused on developing novel protein and conjugate vaccines to prevent bacterial infections. Its pipeline includes candidates targeting pneumococcal disease, periodontal conditions, and other infectious illnesses. This insider purchase arrives as the firm continues advancing its clinical programs toward upcoming milestones.

What to Watch Next for PCVX

Investors will be tracking the company's next financial results on November 3, 2026, along with any further insider filings from executive leadership. Insider transactions can form part of regular personal financial planning and do not necessarily signal a shift in corporate direction.